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COMMENTARY
Advocating for a Medicare Prescription Drug Benefit
John Rother, J.D.*
The health of a people is really the foundation upon which all their
happiness and all their power as a state depend.
-Benjamin Disraeli, 1877
Efforts to enact a prescription drug benefit in Medicare date back
more than forty years. Since then, drugs have continuously grown in
importance; they have also grown in cost. Design and enactment of a
Medicare. drug benefit is therefore one of the most challenging health
policy tasks before Congress. Many policy trade-offs have to be brokered,
powerful interests acknowledged, budget limits respected, and public
expectations rewarded. Ideology and partisan considerations also play a
prominent role. As the benefit finally nears becoming law, as it inevitably
must, the ongoing tension between adequacy and cost-containment has
begun to play out in earnest. In all, the Medicare prescription drug debate
serves as a microcosm of the competing forces that make the American
health care system so challenging to reformers.
AARP (formerly the American Association of Retired Persons) made
enactment of a voluntary, adequate, and affordable prescription drug
benefit its top legislative priority for the past several years. This
Commentary reviews the needs that have given urgency to this effort, the
policy and political considerations surrounding the debate, and the
advocacy strategy that AARP chose to achieve enactment of this benefit.
As this Commentary goes to press, the U.S. Senate and House of
* Policy and Strategy Director, AARP
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Representatives have each passed Medicare prescription drug legislation.
The conference committee, however, has just begun its work. The
legislation's final form remains unknown.
NEED FOR COVERAGE: FINANCIAL BURDENS
Together, Medicare and Social Security were created to provide
financial security to Americans in their later years. But there is no
economic security for older Americans without comprehensive medical
coverage, and there is no comprehensive medical coverage without
prescription drug benefits.
Medicare beneficiaries make up approximately 15% of the population,
yet account for about 40% of U.S. prescription drug spending.' Almost a
third of Medicare beneficiaries-roughly 13 million older and disabled
Americans-have no prescription drug coverage at all. And about 40% of
Medicare beneficiaries lack coverage at some point in the year.' Millions of
others have only partial or unstable coverage.3 This amounts to a
staggering financial burden on millions of older Americans and persons
with disabilities. An estimated 80% of Medicare beneficiaries use a
prescription drug every day and, on average, fill or refill a prescription 24
times a year.4 According to the Congressional Budget Office (CBO),
prescription drug spending for each Medicare beneficiary will exceed
$3000, on average, by 2006.5 The average Medicare beneficiary spends
more out-of-pocket on prescription medications than on physician visits,
medical supplies and vision services combined .
1. Projections of Medicare and Prescription Drug Spending: Hearing Before the S. Comm. on
Fin., 107th Cong. (2002) [hereinafter Hearing] (statement of Daniel L. Crippen, Director,
Cong. Budget Office), available at
http://www.cbo.gov/showdoc.cfm?index=3304&sequence=0 (last visited July 7, 2003).
2. Mary Laschober et al., Trends in Medicare Supplenental Insurance and Prescription Drutg
Coverage, 1996-1999, HEALTH AFFAIRS, Feb. 27, 2002, at W136, at
http://www.healthaffairs.org/WebExclusives/LaschoberWeb-Excl022702.htm (last
visited July 7, 2003).
3. DAvIDJ. GROSS, MEDICARE BENEFICIARIES AND PRESCRIPTION DRUGS: COST AND
COvERAGE (AARP Public Policy Inst., Data Dig. No. 77, 2002), available at
http://research.am-p.org/health/dd77_rx.pdf (last visitedJuly 7, 2003).
4. John A. Poisal & Lauren Murray, Growing Differences Between Medicare
Beneficiaries With and Without Drug Coverage, HEALTH AFFAIRS, Mar./Apr. 2001, at 77.
5. This is an average based on Congressional Budget Office projections. Hearing, supra
note 1, tbl.4.
6. DAVID GROSS & NORMANDY BRANGAN, OUT-OF-POCKET SPENDING ON HEALTH CARE BY
111:2 (2003)
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Elders with no drug coverage lack the comprehensive health benefits
enjoyed by most insured Americans. They also are forced to pay top dollar
for the prescriptions they buy because they are not eligible for the price
discounts negotiated by insurers, managed care companies, and
government health plans. In 1998, for example, Medicare beneficiaries
who lacked drug coverage filled 31% fewer prescriptions than did
beneficiaries with drug coverage, but spent an average ,of 40% more out-of-
pocket on prescription drugs.'
NEED FOR COVERAGE: HEALTH IMPLICATIONS
According to recent studies, Medicare beneficiaries lacking drug
coverage fill about 30 percent fewer prescriptions than do those with
coverage." A recent eight-state survey reported that 22% of older
Americans said they did not fill a prescription because it was too expensive,
or skipped doses of their medications to make them last longer; this
number rose to 35% for elders who lacked prescription drug coverage."
Chronic health problems common to the elderly often require
medications that can total hundreds of dollars a month. Absent Medicare
prescription coverage, many who lack drug coverage or who have
inadequate coverage must choose between the drugs they need to stay
healthy and other life necessities. For example, nearly one-third of the
Medicare-eligible with diabetes, but without drug coverage, skipped doses
or did not fill a prescription. Similarly, about a third of those with heart
disease and without drug coverage reported skipping doses and 25% did
not fill a prescription because of cost. 0
There are serious health consequences to this kind of behavior:
Chronically ill lower-income Medicare beneficiaries who don't take
medications as prescribed are more frequently hospitalized, more likely to
MEDICARE BENEFICIARIES AGE 65 AND OLDER: 1999 PRQIECTIONS (AARP Public Policy Inst.
Publication, In Brief No. 41, 1999).
7. John A. Poisal & Lauren Murray, Growing Differences Between Medicare Beneficiaries With
and Without Drug Coverage, HEALTH AFFAIRS, Mar./Apr. 2001, at 74, 80-81.
8. Id. at 80.
9. Press Release, The HenryJ. Kaiser Foundation, New Survey of Seniors in Eight
States Finds Nearly One in Four Skipping Doses Or Not Filling Prescriptions Due to Cost
(July 31, 2002), http://www.kff.org/content/2002/6049/NewsRelease.pdf (last visited July
7,2003).
10. Dana Gelb Safran et al., Prescription Drug Coverage And Seniars: How Well Are States
Closing The Gap?, HEALTH AFFAIRS, July 31,2002, at
http://www.healthaffairs.org/WebExclusives/2105Safran.pdf (last visitedJuly 7, 2003).
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be admitted to nursing homes, and suffer more dire health outcomes. 1
EXISTING SOURCES OF DRUG COVERAGE
Prescription drug expenditures are the fastest growing component of
health care spending. According to the Centers for Medicare & Medicaid
Set-vices (CMS), total spending on prescription medications is projected to
rise 13.4% in the United States this year to $182.1 billion, or 11.6% of the
nation's $1.66 trillion in health spending.' 2
These costs are forcing insurers and employers to reduce benefits.
Many companies today are reducing or eliminating retiree health
benefits-the primary source of comprehensive drug coverage for the
Medicare-eligible. According to a recent study by the Kaiser Family Fund,
only 21% of companies with more than 200 employees provided health
benefits to Medicare-age retirees in 2001, down from 31% just five years
ago.
Meanwhile, the private insurance market is proving dangerously
volatile for Medicare beneficiaries. Faced with ballooning costs, many plans
available through Medicare+Choice (the Medicare program that allows
beneficiaries to opt into private plans) are increasing premiums and
scaling back drug benefits. In 2003, 66.1% of plans offer some type of drug
coverage in a basic plan, down from 73.4% in 1999.14 Moreover, the
number of plans that do provide coverage, but limit that coverage to
11. See, e.g.,Jan Blustein, Drug Coverage and Drug Purchases by Medicare
Beneficiaries with Hypertension, HEALTI-1 AFFAIRPS, Mar./Apr. 2000, at 219; Stephen B.
Soumerai, Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing
Homes, 325 NEw ENG.J. MED. 1072 (1991); Stephen B. Soumerai et al., Effects of Limiting
Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute
Mental Health Services by Patients With Schizophrenia, 331 NEW ENG. J. MED. 650 (1994).
12. CTRs. FOR MEDICARE & MEDICAID SFRVS., NAIONAL HEALTH CARE EXPENDITURES
PROJEcTiONSTABLEs, tbls.1 & 11, http://cms.hhs.gov/statistics/nhe/projections-2002/ (last
visitedJuly 7, 2003)
13. AARP Public Policy Inst., Employer Health Benefits: 2002 Annual Survey 144, 147
(2003); Kaiser Fain. Found. et al., Erosion of Private Health Insurance Coverage for
Retirees: Findings From the 2000 and 2001 Retiree Health and Prescription Drug Coverage
Survey 2 (2002).
14. It is important to note that these figures apply to any type of Medicare+Choice plan,
not necessarily an HMO and, in 2003, 41.4% of plans with some prescription drug coverage
covered generic drugs only. Eighty-five percent of plans offering 'generic coverage only'
had an unlimited generic benefit. LORI ACHMAN & MARSHA GOLD, MATHEMATICA POLICY
REs., INC., MEDICARE+CHOICE PLANS CONTINUE To SIFT1 MORE COSTS To ENROLLEES (2003).
111:2 (2003)
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"generic drugs only," almost tripled just between 2001 and 2002 (51% vs.
18%). As a result, those Medicare beneficiaries who need medications
available only in brand-name forms have no coverage for those drugs.
1
6
Other Medicare+Choice plans are abandoning the Medicare market
entirely, leaving tens of thousands of patients who relied on the plans for
prescription coverage without recourse. Medicare+Choice plans serving
215,000 enrollees withdrew from the Medicare program or reduced their
service areas effective January 2003, bringing to 2.4 million the number of
beneficiaries who have been dropped by Medicare+Choice plans since
1999.11
While some older Americans purchase additional insurance, known as
Medigap policies, to cover prescription medications, these plans can be
prohibitively expensive and offer only limited benefits.
The combined effect of these problems is that the need for a
prescription drug benefit under Medicare is greater than ever.
BENEFIT DESIGN ISSUES
AARP is committed to pursuing a Medicare prescription drug plan
that is voluntary, reliable, affordable, provides adequate benefits, and is
available to all beneficiaries. Political and financial constraints, however,
pose significant challenges to achieving these goals.
Consumer acceptance of any prescription drug plan is critical.
Consider the case of the Medicare Catastrophic Coverage Act of 1988, an
effort by Congress in the late 1980s to protect beneficiaries from
15. LORI ACHMAN & MARSnA GOLD, THE COMMONWEALTH FUND, MEDICARE+CHOICE:




17. CTRS. FOR MEDICARE & MEDICAID SERVS., CY 2002 NONRENEWAL REPORT BY STArE,
COUNlY, PLuAN, http://%,ww.cms.gov/healthplans/nonrenewal/markprintedoutmew.asp
(last visitedJuly 7, 2003); CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE+CHOICE
NONRENEWAL REPORTS CY 2001,
http://www.cms.gov/healthplans/nonrenewal/reports2001.asp(tast visitedJuly 7, 2003);
CTRS. FOR MEDICARE & MEDICAID SERVS., MEDICARE+CHOICE NONRENEWAL REPORTS CY 2003,
http://cms.bhs.gov/healthplans/nonrenewal/reports2003.asp (last visitedJuly 7, 2003);
MEDPAC, REPORT TO CONGRESS, MARCH 2000,
http://www.medpac.gov/publications/congressional-reports/MarOO Table of Contents.pdf
(last visitedJuly 7, 2003).
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"catastrophic" medical bills not covered by Medicare. ' The goal was to
provide a safety net for those with the highest out-of-pocket medical
expenses. But the legislation drew fire from many of the very beneficiaries
it was enacted to help-in part because lawmakers made premiums
mandatory and added an income-related premium of up to $800 per year,
even for those older Americans who already had drug coverage through
employer health benefits or other privately-purchased insurance plans.
Rallying behind the slogan "Repeal the Seniors-Only Surtax,"
opponents waged a successful protest even as public opinion polls showed
that most seniors with low-to-modest incomes supported the legislation.
The catastrophic bill was repealed before it could be implemented.
That experience taught Congress an important lesson: Public support
is essential. For Medicare beneficiaries, any new benefit must be both
affordable and voluntary. But as lawmakers have discovered, it is difficult to
provide a voluntary comprehensive prescription plan that includes the
benefits older Americans expect at a price they can afford.
Older Americans will only buy into the program if they feel they are
saving money, which is difficult to do if the program is covering the cost of
insuring both low-income beneficiaries and the "high-cost" patients with
expenses beyond four or five thousand dollars a year.
For a viable program, premiums must be reasonably priced to attract
middle class and relatively healthy beneficiaries. Otherwise, only high-risk
beneficiaries-including patients with chronic conditions or higher-than-
average drug costs-will buy in to the plan-a situation known as "adverse
selection." If primarily high-cost beneficiaries bought in, an insurance
"death spiral" could ensue, as premiums spiraled upward, and only those
with the most expensive medical needs remained in the plan. If the cost of
care exceeded the premiums collected and continuously forced increases
in premiums, the plan would eventually fail.
Unfortunately, without federal support, the proposals under
consideration could be priced far higher than most older Americans are
willing or able to pay. Therefore, the only way to make a Medicare
prescription benefit economically feasible is to factor in a significant
federal contribution-a challenging prospect given current budgetary
constraints.
CONGRESSIONAL DEBATE
In June of 2002, the United States House of Representatives passed a
18. Medicare Catastrophic Coverage Act of 1988, Pub. L. No. 110-360, 102 Stat. 683.
111:2 (2003)
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$310 billion (over ten years) Medicare prescription drug bill that relied
primarily on at-risk private insurers to administer the benefit. It also
contained a significant gap in the benefit that critics dubbed the
"doughnut hole." In July of 2002, the Senate tried and failed four times
with four separate bills to muster the sixty votes necessary to pass its own
version of a Medicare drug plan. Ninety-nine Senators voted for competing
versions of a benefit, but could not reach a bipartisan compromise to reach
the sixty-vote threshold required in the Senate to overcome points of
order.
Despite this failure, Senators implicitly reached agreement on several
key points, most notably, a commitment to fund the program with at least
$400 billion over ten years-still an amount less than many consider
necessary for a meaningful benefit. In addition, there was bipartisan
agreement to offer coverage to all Medicare beneficiaries, to subsidize
costs for low-income beneficiaries and those with the highest drug costs,
and to cap the amount beneficiaries would have to spend out-of-pocket at
approximately $4,000 a year.
But partisan and policy disputes ultimately killed the chance for
legislative compromise in the Senate in 2002. At issue were three primary
points of contention:
1. Benefit design: The "doughnut hole" gap in benefit coverage would
have affected almost one third of Medicare beneficiaries who have drug
costs above $3,450 per year. Republicans were unwilling to allocate the
funding necessary to close that gap, while Democrats generally saw it as a
barrier to beneficiary acceptance and incompatible with the goal of
financial protection that is the rationale for a benefit.
2. Who bears risk: Democrats generally believe that government should
run the program and bear the risk of cost overruns, just as Medicare
currently accepts cost overruns for other parts of the healthcare system.
Republicans prefer to put delivery in the hands of private insurers, who
would compete for the enrollment of beneficiaries. They believe that such
entities could be more flexible in achieving cost savings and, because they
would be at financial risk, would have a strong incentive to do so.
Democrats counter that relying on private insurers would only add
overhead costs and could leave beneficiaries vulnerable if profits suffer and
companies pull out of the market.
3. Asset test. Republican proposals impose both an asset test and an
income test on beneficiaries who want to qualify for more generous low-
income assistance, primarily as a means of saving money. Democrats
generally view this as stigmatizing and a barrier to enrollment, and, as a
matter of principle, do not want to introduce asset tests into a social
7
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insurance program.
Last fall, Medicare prescription coverage proved a potent political
issue in congressional campaigns across the country. In fact, almost all
successful candidates pledged to enact a benefit in 2003. As a result,
Congress convened in January with the understanding that it had to
produce a benefit.
In addition to the issues mentioned above, the 108th Congress faces a
heightened need for even tougher cost containment mechanisms, as well
as a push for broader Medicare reforms, to accompany a drug benefit. The
election gave Republicans control of the Senate and a greater margin in
the House. President Bush designated $400 billion in his annual budget
proposal for Medicare reform and a prescription drug benefit. Bipartisan
legislation in the Senate (S. 1) passed in the early hours of June 28 ". The
House followed hours later, passing H.R.1 by a single vote. Both bills
combined a modest and voluntary prescription drug benefit with various
"structural reforms" that increased the role of the private sector in
Medicare. Both bills made changes to current benefits in Part B, and
increased rural provider payment rates. Finally both bills structured the
prescription drug benefit to primarily assist lower-income beneficiaries and
those with the highest level of drug expenses.
As this Commentary goes to press, AARP has commented extensively
on both bills and has written a detailed letter to the conferees expressing
substantive concerns and recommendations. AARP is withholding
judgment on a conference report, pending resolution of these items. The
issues addressed in this Commentary remain central to the final legislative
debate, with AARP's advocacy more intensive than ever in promoting an
affordable, universal and workable benefit program.
COST CONTAINMENT STRATEGIES
Beyond the promise of an added benefit is the issue of how to keep it
affordable over time, especially when drug costs are projected to increase
at double-digit rates. A range of initiatives has been proposed. One such
measure is a prescription discount card proposed by the Bush
administration. Health and Human Services officials estimate that the card
would save 10%-13% on eligible cardholders' out-of-pocket prescription
costs, or an average of $170 per year. Government funding would not
provide these discounts. It is anticipated that decreases would largely be
possible from discounts Pharmacy Benefit Managers (PBMs) will negotiate
from pharmacies and, less likely, from drug manufacturers.
Additional cost savings will be necessary. The reality is that any
111:2 (2003)
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comprehensive plan requires hard choices. The only way to have a
sustainable drug benefit is to put in place mechanisms that contain costs
and keep premiums affordable for beneficiaries.
Prescription prices in the United States are driven in part by the desire
by drug manufacturers to recoup quickly their research, development, and
capital costs-an investment now rewarded with twenty-year patents on
new drugs that limit competition and delay the introduction of less-
expensive generic alternatives. For this reason, among others, many in
Congress have been reluctant to impose price controls, common in other
countries, on pharmaceuticals. One way to control costs is through
pharmacy benefit managers (PBMs), which negotiate discounts with drug
manufacturers and pharmacies, and channel more prescription business
through low-cost mail-order pharmacies.
A cost-sensitive prescription drug plan must also promote wider use of
less expensive generic drugs where medically appropriate. Generics now
account for 42% of all prescriptions filled, but potentially offer much
greater savings: The Food and Drug Administration (FDA) estimates that
nearly 60% of the most common brand name medications have cheaper
generic equivalents, a figure expected to rise as patents on popular drugs
expire over the next few years. In July of 2002, the United States Senate
debated legislation (known as McCain/Schumer) that would have
reformed federal patent law to promote price competitions and allow
faster market access to generics. The bill would have closed loopholes in
United States patent law that have allowed manufacturers to delay the
introduction of generics to compete with name-brand drugs. According to
an estimate by the CBO, the legislation would have reduced total spending
on prescription drugs by $60 billion over the next ten years. The bill was
approved by the Senate in 2002 but died in the House of Representatives.
A modified version, with less savings, was approved in 2003 and included in
the Medicare legislation by both the Senate and the House.
In addition, many states are implementing "preferred drug lists"
(PDLs) and other measures to expand the use of generics and lower-cost
brand-name drugs in their Medicaid programs. This could motivate
manufacturers to reduce prices in order to remain competitive. This
approach uses techniques applied by PBMs in the private sector to identify
the most effective medication at the least cost. PDLs have substantially
lowered state Medicaid drug expenditures and have prevented states from
adopting more draconian cuts in their Medicaid programs, such as limiting
eligibility.
But these approaches are not without controversy. Drug
manufacturers are fighting many cost-control measures, and PhRMA, a
9
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pharmaceutical trade group, has filed suit in federal court to block
Medicaid PDLs.' 9 PhRMA contends that such programs illegally restrict
access to drugs. Many retail pharmacies oppose PBMs, claiming that
pharmacy benefit managers set reimbursement rates to pharmacies too low
to cover the cost of services they provide, and rely on mail-order
pharmacies that could drive traffic away from community drugstores.
Finally, any successful cost-containment initiative must address value.
Some drugs produce little additional benefit for great additional cost.
There is to date little research to determine the comparative efficacy of
particular drugs. This is missing information that could direct cost control
approaches to lower overall costs without lowering health benefits.
Developing such studies is expensive, but needs to be a national priority.
Funding for efficacy research could be repaid several times over in the
long term by focusing coverage expenditures on appropriate and effective
medications.
MEDICARE STRUCTURAL REFORM
A second issue before the 108th Congress is broader Medicare reform.
Many insurance analysts believe that a voluntary, stand-alone prescription
drug product is not viable because only the sickest beneficiaries would be
certain to apply. An alternative is to place a drug benefit in the context of
broader insurance benefit packages that would be associated with broader
Medicare reforms. Under this approach, beneficiaries could choose to
enroll in a "high option" set of Medicare plans that trade higher premiums
for an improved benefit package. Republican health leaders have long
favored a greater role for private plans in Medicare. They view a
prescription drug benefit as the "carrot" that will permit broader
restructuring than would otherwise be politically possible.
Medicare structural reform, however, complicates both the design
issues and the politics of achieving a drug benefit. Design issues take into
account the need to reform the entire Medicare benefit structure,
complicating the risk of pooling relationships between the original
Medicare program and any new alternatives. Established ways of
reimbursing providers for care may be affected, and reforms are likely to
add to the total costs of a legislative proposal, at least for the near future.
These issues had the potential to make or break the prescription drug
drive to enactment in 2003. Like most other aspects of healthcare, the
interrelationships among all aspects of financing, delivery, cost-
19. See, e.g., Pharm. Research & Mfrs. of Am. v. Walsh, 123 S. Ct. 1855 (2003).
111:2 (2003)
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containment and consumer acceptance make Medicare policy-making
especially difficult.
AARP's ADVOCACY STRATEGY
AARP is the voice of the beneficiary, so we adopted a consumer-driven
strategy. We have used all of the advocacy tools available to us to keep the
concerns and views of beneficiaries before policy-makers, to present
preferred solutions to the design and political challenges involved, and to
keep the legislative momentum moving forward. We see ourselves as the
key bridge between the political parties. We also act as a principal
"validator" to the public for the worthiness of various proposals.
Our fundamental strategy has been to apply enough pressure on the
Congress and the industry to break the legislative and political logjam.
Given the budget constraints set by the White House, the proposed
program was unlikely to be seen as adequate. Out of a projected total
nationwide expenditure for prescription drugs of 1.8 trillion over the next
ten years, the program would cover less than one-quarter of costs.
Nevertheless, if a solid foundation was established, it could be built upon
in future years. If assistance was targeted to lower-income beneficiaries and
those with high expenses, the most pressing immediate needs would be
met. Waiting for a more favorable budget allowance in future years seemed
hazardous at best.
AARP played a crucial role in this campaign, mainly due to the clout of
our thirty-five million members. We also developed a unique set of
advocacy tools to employ in this effort. The challenges inherent in this
effort required that all of these tools be used effectively in order to mount
a successful campaign.
To support our ongoing advocacy strategy, we:
" Sponsor an active program of consumer polling and focus
groups;
* Employ sophisticated economic policy analysis and modeling,
including actuarial models and budgetary forecasting tools;
* Call upon our grassroots base and thousands of dedicated
community-based volunteer advocates;
* Host candidate debates and town meetings during elections,
although we do not fundraise for candidates or endorse them;
* Compile voters' guides based on candidate responses to our
questions and distribute them to our members;
* Publish a monthly newspaper that features regular reporting
on the progress of the campaign and on the urgency of the
11
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problems. This newspaper goes to all AXRP members, making
it the largest circulation newspaper in the country;
* Sponsor radio interviews and television news spots that are
broadly distributed to stations;
* Litigate to keep pressure on the industry to limit anti-consumer
practices, and to make sure that laws are interpreted and
enforced consistent with their intent;
* Advocate for state-based pharmaceutical assistance while the
congressional debate continues. We believe that the state
experience can contribute to the development of good policy,
whether on cost-containment or the administrative
arrangements involved in administering the benefit. To
support this effort, AARP has staffed offices in every state;
" Join coalitions with other interested parties, such as business
leaders, insurers, and governors. These coalitions are especially
helpful in formulating consistent advocacy messages from a
range of perspectives, and in building a broader base of
support for particular aspects of legislation; and
* Engage in face-to-face lobbying in both the Congress and the
Executive Branch to communicate about all of this work, to
exchange ideas, and to respond to the ideas of others.
Although our small handful of lobbyists who work on this issue
are greatly outnumbered by the paid lobbying efforts of the
pharmaceutical industry and other interests, it is the grassroots,
analytical, and communications structure that supports those
lobbyists that gives their work the impact that it has.
This advocacy strategy in 2003 was grounded in a sense of urgency.
While design, political, and budgetary challenges are always serious, it is
crucial to remember that delay also has a price. For many disabled and
older Americans, this is not just a matter of dollars, it is also a matter of
access to the drugs they need to stay healthy and stay alive. Nearly forty
years ago, President LyndonJohnson signed Medicare into law, promising
that "no longer will older Americans be denied the healing miracle of
modern medicine." Today, prescription medications are a crucial
component to that healing miracle. Without prescription benefits, the
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